Due to recent changes in the official account push mechanism, we welcome you to set Boom Health as a "starred" account on the homepage of the official account to get the latest trends and expert insights in the digital healthcare industry第一时间!
01 Global Digital Health Investment and Financing OverviewAR Smart Glasses Developer Rokid Completes Nearly 500 Million Yuan in C+ Round FinancingOn January 9, Rokid completed a nearly RMB 500 million C+ round of financing. This round was led by the Hefei Municipal Government, with participation from multiple financial and strategic investment institutions. The funds will be used to enhance B-end services and production-research capabilities, as well as to build an XR ecosystem in Hefei. The company's medical industry solution, the AR+5G Smart Medical Platform, effectively addresses regional healthcare resource imbalances through intelligent diagnosis and treatment and remote consultation.Chemical Synthesis CRO Service Provider Meirui Chemistry Completes $26 Million Series A FinancingOn January 9, contract research organization (CRO) service provider in chemical drug synthesis, Shanghai Meirui Technology Co., Ltd. (Meirui Chemical), completed a US$26 million Series A financing round. This round was co-led by Qiming Venture Partners and LYFE Capital, with participation from Innovation Works and MegaRobo Technologies. The proceeds will be used to further enhance product development, expand commercial markets, and support international expansion.Spinal Surgery Robot Developer LEM Surgical Raises CHF 22 Million in Series B FundingOn January 4, LEM Surgical, a developer of spinal surgical robots, secured CHF 22 million in a Series B financing round. The funds will advance the development of its robotic spinal surgery system and prepare for submission to the U.S. Food and Drug Administration (FDA).AI Doctor Assistant Platform Nabla Secures $24 Million in Series B FundingOn January 5, AI doctor assistant platform Nabla secured $24 million in Series B funding, led by Cathay Innovation with participation from ZEBOX Ventures. In addition to expanding across China, the new funding will further advance the development of its AI platform to support clinical doctors. Moreover, Nabla Copilot will introduce additional language options to facilitate its expansion into more regions.Digital Addiction Treatment Provider PursueCare Completes $20 Million Series B FinancingOn January 5, digital addiction treatment provider PursueCare completed a $20 million Series B financing round, led by T.Rx Capital and Yamaha Motor Ventures, with participation from Seyen Capital and OCA Ventures. The funds will support PursueCare's ongoing collaborative care programs with health systems across 11 states, as well as expand into value-based care through Medicaid managed care and other health plans.Dental Robotics Developer Neocis Secures $20 Million in FinancingOn January 10, Neocis, a dental robotics developer, secured $20 million in funding from investors including Mirae Asset Capital/Mirae Asset Venture Investment and NVentures. The funds will be used for market expansion of the company’s products and to drive innovation in the dental implant field.Wearable Device Developer Cionic Secures $12 Million in Series A FundingOn October 20, wearable device developer Cionic secured a $12 million Series A extension round led by L Catterton, with participation from THVC, bringing the total funding in this round to $25 million. The funds will be used to further expand the company’s product applications and accelerate its product line into new indications such as multiple sclerosis, stroke, cerebral palsy, and other neurological disorders.AI-Driven Medical Record Aggregation Platform DigitalOwl Raises $12 Million in FinancingOn January 9, DigitalOwl, an AI-driven medical record summarization platform, secured $12 million in funding from RGA. The company uses artificial intelligence to interpret medical records and convert them into interactive digital underwriting summaries. Following this round of financing, DigitalOwl's technology will be integrated as a core component into RGA’s internal underwriting operations.Care Continuity, a provider of care coordination solutions, secures $10 million in Series A3 fundingOn January 8, Care Continuity, a care coordination solutions provider, announced the completion of its $10 million Series A-3 financing round, led jointly by Empactful Capital and Viewside Capital Partners, with participation from Flat Creek Capital and Loop 289 Limited Partners.Value-Based Care Service Intermediary Platform Arbital Health Raises $10 Million in Series A FundingOn January 4, Arbital Health, a value-based care services intermediary platform, secured $10 million in Series A funding. The round was led by Transformation Capital. The company also acquired Santa Barbara Actuaries, an actuarial and healthcare consulting firm. Through this acquisition, Arbital Health will provide an actuarial team focused on value-based care.XRHealth Announces $6 Million in Funding for Virtual Therapy Service PlatformOn January 9, virtual treatment service platform XRHealth announced that it had raised $6 million in funding, led by Asabys Partners. This round of financing marks the completion of the merger between XRHealth and Amelia Virtual Care, providing support for the development of the merged entity. The funds will also further advance the development of AI-based clinicians, who can treat patients' mental health conditions and guide them through physical and occupational therapy programs.Clinical Decision Technology Researcher Credo Health Secures $5.25 Million in Seed FundingOn January 5, clinical decision technology developer Credo Health announced a $5.25 million seed funding round led by FCA Venture Partners. The funds will be used to enhance Credo Health's value-based healthcare services. Its core platform, PreDx, provides comprehensive clinical information for each patient while supporting risk adjustment, quality, and health equity.Dongguan Yuansheng Intelligent Technology Co., Ltd. Secures RMB 10 Million in Angel Funding for Smart Rehabilitation Equipment DevelopmentRecently, Yuansheng Intelligent Technology, a developer of intelligent rehabilitation care equipment, has secured tens of millions in angel funding. This round was strategically led by the listed company CloudWalk Technology, one of China's AI "Four Little Dragons." Investors included Songshan Lake Angel Fund, Zhuhai Industrial Research Institute of Guangdong Academy of Sciences, founder of Spark Education (an existing shareholder), and Qingrong Venture Capital (another existing shareholder). The funds will reportedly be used for product manufacturing, technology research and development as well as iteration, marketing promotion, and new product development.Digital Precision Mental Health Company Feel Therapeutics Secures New FundingOn January 9, Feel Therapeutics, a digital precision healthcare company specializing in mental health, secured new funding from investors including Satori Neuro, SOSV, and SeedtoB. The company develops digital biomarkers and therapies, offering a patient support program for mental health combined with remote health monitoring, as well as the digital therapeutics platform Feel DTx, which delivers digital cognitive behavioral therapy to treat patients with major depressive disorder and/or generalized anxiety disorder.02 Digital Health Industry Dynamics
Menarini Collaborates with Insilico MedicineOn January 5, Menarini, together with its wholly-owned subsidiary Stemline Therapeutics, reached a licensing agreement with Insilico Medicine. Menarini has obtained the global exclusive rights for the development and commercialization of ISM5043, a novel small molecule inhibitor targeting KAT6 that was designed and developed with the assistance of Insilico Medicine’s artificial intelligence platform. ISM5043 is expected to be used in the treatment of ER+/HER2- breast cancer and other cancers. According to the terms of the agreement, the total value of the collaboration between the Menarini Group and Insilico Medicine exceeds 500 million US dollars, including an upfront payment of 12 million US dollars as well as subsequent development, regulatory, and commercial milestones.AbbVie and Umoja Biopharma Reach CollaborationOn January 4, AbbVie and Umoja Biopharma announced two exclusive option and license agreements with a potential total value exceeding $1.4 billion. The two companies will utilize Umoja's proprietary VivoVec platform to develop multiple in-situ generated CAR-T cell therapy candidates in the field of oncology.MediLink Collaborates with RocheOn January 2, MediLink announced that it had reached a global collaboration and licensing agreement with Roche. The two parties will collaborate to develop YL211 (c-MET ADC), a next-generation antibody-drug conjugate candidate targeting mesenchymal-epithelial transition factor (c-MET), for the treatment of solid tumors. Roche will pay MediLink an upfront payment and near-term milestone payment of 50 million USD, along with potential development, regulatory, and commercialization milestone payments of up to nearly 1 billion USD.03 Global Digital Health M&A OverviewGE Healthcare Announces Acquisition of MIM SoftwareOn January 8, GE Healthcare announced plans to acquire MIM Software, a provider of artificial intelligence and medical imaging analysis. The two parties have reached an acquisition agreement, and the specific financial terms have not been disclosed. GE Healthcare plans to integrate MIM Software's innovative solutions into its advanced visualization products to promote the application of digital technologies, such as AI-based lesion segmentation and target area delineation, as well as dose analysis in radiation therapy, across all stages of disease diagnosis and treatment—especially in the rapidly growing fields of radiology, nuclear medicine molecular imaging, and radiation oncology.Boston Scientific Acquires Axonics, Strengthening Urology Neuromodulation Product LineOn January 8, Boston Scientific Corporation announced that it had reached a definitive agreement to acquire Axonics. The acquisition price is $71 per share, which is more than 20% higher than Axonics' closing price the Friday before the announcement. The total equity value is approximately $3.7 billion, and the enterprise value is about $3.4 billion after deducting Axonics' cash and equivalents of approximately $300 million. The two companies expect to complete the transaction in the first half of this year, and Axonics will become a wholly owned subsidiary.Novartis Announces Acquisition of Xinruinuo PharmaceuticalOn January 5, Novartis announced the acquisition of Xinruinuo Pharmaceutical to further strengthen its presence in the renal disease field. Upon completion of the acquisition, Xinruinuo will be fully integrated into Novartis China and become an indirect wholly-owned subsidiary of Novartis. This acquisition is expected to expand Novartis' renal disease product portfolio in China, enriching its future pipeline to better meet the treatment needs of patients with renal disease in the country.MSD Acquires Harpoon TherapeuticsOn January 4, MSD announced the acquisition of Harpoon Therapeutics for $23 per share, totaling $680 million, to strengthen its oncology portfolio. MSD will pay $23 in cash for each issued and outstanding share of Harpoon, which is 118% higher than Harpoon's closing price of $10.55 last Friday. This acquisition will further expand MSD’s oncology pipeline and advance groundbreaking scientific developments to meet the needs of cancer patients worldwide.ArteryNet/Arterial Orange Industry Think Tank/China Renaissance/BGI Co-Win/Rock Health/Mobile Health News/FierceHealth, etc.
Compiled by: Zhang Qiankun
